Orion Corporation

Orion Corporation is a Finnish pharmaceutical company founded in Helsinki in 1917. The company develops, manufactures and markets medicines for human and veterinary use, as well as active pharmaceutical ingredients for international markets. Its principal corporate base is in Espoo, while its manufacturing operations and most of its research and development activities are located in Finland. The company began as a small pharmaceutical enterprise established by pharmacists Onni Turpeinen, Eemil Tuurala and Wikki Valkama. Its first premises were in a courtyard building on Mariankatu in Helsinki's Kruununhaka district. Early products included Ballistol gun oil and the sweetener dulcine, reflecting the broad product mix of an emerging pharmaceutical and chemical business. During the 1920s, pediatrician Arvo Ylppö became an important influence in Orion's development and in the company's relationship with Finnish medicine. Over time, Orion evolved from a domestic pharmaceutical producer into a research, manufacturing and commercial organization serving global markets. Its activities cover prescription medicines, over-the-counter products, veterinary pharmaceuticals and pharmaceutical ingredients. The company is particularly associated with neurology and respiratory medicine, while also operating in other specialized areas including intensive care and hospital-related treatments. Orion combines internally developed products with manufacturing, licensing and commercial partnerships, although the available reference material does not provide a complete current portfolio or a definitive list of all partner products. Orion's business has also changed through portfolio decisions. Its diagnostics activities were formerly organized in the Orion Diagnostica profit unit. That business developed, manufactured and marketed diagnostic and hygiene tests, but it was sold to a private-equity investor in April 2018. Following the transaction, the business adopted the name Aidian in November 2019 and no longer formed part of Orion's operating portfolio. The divestment illustrates Orion's concentration on pharmaceutical and pharmaceutical-ingredient activities rather than on diagnostics. The company operates internationally but retains a strongly Finnish industrial and research base. All of its manufacturing sites and most of its research and development units are in Finland, while its products are marketed in global markets. Orion's Class A and Class B shares are listed on the Helsinki Stock Exchange. The reference material identifies Orion as an active, publicly listed pharmaceutical company, but does not provide enough current information to state a complete leadership roster, detailed revenue history, current product-level sales ranking or a comprehensive account of recent corporate developments.

Orion Corporation was established in Helsinki on September 21, 1917, by pharmacists Onni Turpeinen, Eemil Tuurala and Wikki Valkama. Before founding the company, the three had worked at Medica, a pharmaceutical-chemical factory. Orion's earliest premises were located in a courtyard building at Mariankatu 24 in Helsinki's Kruununhaka district. The company's initial activities reflected the varied product base of an early pharmaceutical enterprise; among its first products were Ballistol gun oil and dulcine. During the 1920s, pediatrician Arvo Ylppö played an important role in Orion's development. His involvement connected the young company with Finnish medical practice and contributed to its early pharmaceutical orientation. Across the following decades, Orion developed into a broader medicine business, eventually serving both human and veterinary markets and expanding into the production of active pharmaceutical ingredients. In its mature form, Orion became a globally operating Finnish pharmaceutical company. Although it markets products internationally, its manufacturing infrastructure and most of its research and development units remain in Finland. The company's activities include the development, manufacture and marketing of pharmaceuticals and ingredients, with particular emphasis on therapeutic areas such as neurology and respiratory medicine. It also has activities associated with hospital and intensive-care treatments, alongside broader human and veterinary pharmaceutical offerings. Orion's corporate scope has not remained static. Diagnostics was previously organized as the Orion Diagnostica profit unit. That business covered diagnostic tests and hygiene tests, including their development, manufacture and marketing. In April 2018, Orion sold the diagnostics operation to a private-equity investor. The separated business changed its name to Aidian in November 2019. The transaction marked a strategic narrowing of Orion's portfolio toward pharmaceuticals and pharmaceutical ingredients. Orion is a publicly listed Finnish company. Its Class A and Class B shares are listed on the Helsinki Stock Exchange. The available reference material does not identify a current executive team, provide a complete chronology of product launches or partnerships, or document any major scandals. Those areas therefore remain unexpanded rather than being supplemented with unsupported claims.

• 2019

  Former diagnostics unit becomes Aidian

  [1]Orion Corporation (Finnish company)en.wikipedia.org

  The divested diagnostics business changes its name from Orion Diagnostica to Aidian in November.

• 2018

  Diagnostics business is divested

  [1]Orion Corporation (Finnish company)en.wikipedia.org

  Orion sells its Orion Diagnostica diagnostics business to a private-equity investor in April.

• 1920

  Arvo Ylppö becomes an important early influence

  [1]Orion Corporation (Finnish company)en.wikipedia.org

  Pediatrician Arvo Ylppö plays a significant role in Orion's early development during the 1920s.

• 1917

  Orion is founded in Helsinki

  [1]Orion Corporation (Finnish company)en.wikipedia.org

  Onni Turpeinen, Eemil Tuurala and Wikki Valkama establish Orion on September 21, 1917. The first premises are located at Mariankatu 24 in Helsinki's Kruununhaka district.

A Finnish, research-based pharmaceutical company emphasizing human and veterinary medicines, active pharmaceutical ingredients and specialized therapies, with particular strengths in neurology and respiratory care.

• Prescription and over-the-counter medicines

  Human pharmaceuticals

  Orion develops, manufactures and markets medicines for human use. The company's stated therapeutic emphasis includes neurology and respiratory care, with additional products serving specialized and hospital-related medical needs. The available reference material does not identify a complete current list of branded medicines.

• Veterinary medicine

  Veterinary pharmaceuticals

  Veterinary medicines form part of Orion's pharmaceutical business. The company develops, manufactures and markets products for animal health in addition to its human-medicine activities. Specific current brands and product launches are not identified in the supplied sources.

• Pharmaceutical ingredients

  Active pharmaceutical ingredients

  Orion produces and markets active pharmaceutical ingredients for global markets. This activity supports the company's role across the pharmaceutical value chain, alongside medicine development and finished-product manufacturing.

• Diagnostics

  Diagnostics and hygiene tests

  Diagnostics and hygiene tests were formerly developed, manufactured and marketed through Orion Diagnostica. This business was sold in 2018 and later operated under the Aidian name, so it is no longer an Orion product line.

• 2018

  Divestment of Orion DiagnosticaM&A

  Background

  Orion's diagnostics activities included diagnostic and hygiene tests but were separate from its core pharmaceutical and active-ingredient operations.

  Action taken

  Orion sold the diagnostics business to a private-equity investor in April 2018.

  Aftermath

  The business was separated from Orion and changed its name to Aidian in November 2019. The transaction reinforced Orion's focus on pharmaceuticals and pharmaceutical ingredients.

  Source

• Unconfirmed

  Orion Corporation completed share acquisitions[3]Orion Corporation完成股份收购news.google.com

  Reported: 2026-09-30

  Orion Corporation completed share acquisitions, as reported in a GlobeNewswire notice dated 2026-09-30. The source text does not specify the shares acquired, the counterparty, or the completion date.

1. 1Orion Corporation (Finnish company)en.wikipedia.org
2. 2Orion Corporation official websiteorion.fi
3. 3Orion Corporation完成股份收购news.google.com